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Background: Increased oxidative stress is supposed to be involved in the etiology of idiopathic pulmo-
nary ﬁbrosis (IPF). It was reported that oxidative stress values measured by a spectrophotometric
technique (d-ROMs test) were signiﬁcantly higher in IPF patients than in controls, and were negatively
correlated with Forced Vital Capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO). However,
the relationship between progression of IPF over time and change in serum oxidative stress marker
remains unclariﬁed.
Aims: This study aimed to investigate the change in serum oxidative stress marker during progression of
IPF.
Subjects and methods: The levels of oxidative stress in blood samples of 43 treatment-naïve IPF patients
were measured by the d-ROMs test. FVC and DLCO were measured concurrently. The changes in
oxidative stress and pulmonary function were evaluated in 27 untreated patients 6 months later.
Oxidative stress levels of 13 patients with acute exacerbation of IPF (AE-IPF) and 30 healthy controls were
also evaluated.
Results: Oxidative stress values [median, interquartile range (IQR); Carratelli units (U.CARR)] were
signiﬁcantly higher in 43 IPF patients than in controls (366, 339e443 vs. 289, 257e329, p < 0.01) and
were signiﬁcantly increased 6 months later in 27 untreated patients (353, 311e398 at baseline to 385,
345e417 at follow-up, p < 0.01). The increase in oxidative stress values (24.0, 6.0e49.0 U.CARR/6
months) was negatively correlated with baseline DLCO (rs ¼ 0.44, p < 0.05) and FVC changes after 6
months (rs ¼ 0.54, p < 0.01). Oxidative stress values were signiﬁcantly higher in IPF patients with acute
exacerbation than in those with stable disease (587, 523e667 vs. 366, 339e443 U.CARR, respectively;
p < 0.01).
Conclusions: Serum oxidative stress values increased with disease progression in IPF patients.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Idiopathic pulmonary ﬁbrosis (IPF), a progressive disease with
an as yet unidentiﬁed cause, is often fatal and characterized by
irreversible change in alveolar structure by ﬁbroblast growth and
remodeling of extracellular matrix [1].
IPF is a disease with poor prognosis, and the median survival
time is 2.5e3.5 years. The clinical course of individual patientsMedicine, Toho University
Sakura City, Chiba 285-8741,
(Y. Matsuzawa).
Ltd. This is an open access article uvaries from slow to rapid progression [2]. Unpredicted acute
exacerbation that develops in some patients is often fatal [3].
Pathohistologically, IPF exhibits usual interstitial pneumonia
(UIP), which is characterized by various levels of ﬁbrosis in time
and space, scarring and honeycombing along with areas of unaf-
fected parenchyma, and by a paucity of inﬂammatory ﬁndings. The
centers of growth of ﬁbroblasts are called “ﬁbroblastic foci” which
seem to appear at sites of alveolar injury [4].
It has been long believed that pulmonary ﬁbrosis begins with
alveolar inﬂammation and that chronic inﬂammation modulates
ﬁbrogenesis [5]. However, the clinical degree of inﬂammation
showed no correlation with disease severity or clinical course, and
treatment with anti-inﬂammatory drugs failed to improve thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of patients with idiopathic pulmonary ﬁbrosis (IPF) and controls.
IPF Control
N 43 30
Sex, m/f 33/10 23/7
Age, yr 69.4 ± 8.9 65.0 ± 11.5
Smoker/ex-smoker/nonsmoker 0/32/11 0/23/7
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a major role in the etiology and that abnormal wound healing in
response to alveolar epithelial injury results in lung ﬁbrosis [6].
It has been found that oxidative stress is increased in IPF and is
involved in its pathogenesis. Cantin et al. demonstrated that cells in
the bronchoalveolar lavage ﬂuid (BALF) produced oxidants and
myeloperoxidase at higher concentrations in IPF patients than in
control patients. They also showed that increased peroxidase ac-
tivity was involved in the epithelial injury in IPF [7]. Jackson et al.
reported that free radical activity was increased based on the
change in serum markers [8], while Rahman et al. showed an
imbalance between oxidative stress and anti-oxidative potency in
serum and BALF in IPF patients [9].
The Diacron Reactive OxygenMetabolites test (the d-ROMs test)
is a method to evaluate oxidative stress of the whole body by
measurement of the total content of hydroperoxide in the blood
[10]. Daniil et al. reported that serum oxidative stress values
measured by the d-ROMs test were signiﬁcantly higher in 21
treatment-naïve IPF patients than in controls, and were negatively
correlated with Forced Vital Capacity (FVC) and Carbon Monoxide
Diffusing Capacity (DLCO) [11].
However, the relationship between progression of IPF over time
and change in serum oxidative stress values remains unclariﬁed.
The relationship between acute exacerbation (AE) of IPF (AE-IPF)
and oxidative stress also remains unclear. The aim of this study was
to investigate how serum oxidative stress values would change as
IPF deteriorated over time.
2. Subjects and methods
2.1. Subjects and methods
Among all IPF patients who visited our department between
January 1, 2009 and September 30, 2012, 47 of them who were not
treated with oxygen, steroids, immunosuppressants, pirfenidone, or
N-acetylcysteine were subjected to measurement of serum oxidative
stress values. IPF was diagnosed according to the criteria of ATS/ERS/
JRS/ALAT statement for IPF [1]. After exclusion of pulmonary ﬁbrosis
due to collagen disease, professional exposure, hypersensitivity
pneumonitis, and drug-induced lung disease, high-resolution CT
(HRCT) images were evaluated by more than one respiratory
specialist and experienced radiologists for conﬁrmation of the usual
interstitial pneumonia (UIP) pattern. No surgical biopsy was carried
out. After exclusion of two cases each of suspected chronic airway
infection and conﬁrmed concurrence of a malignant tumor, the
relationship between oxidative stress values and pulmonary func-
tion was retrospectively examined in the remaining 43 cases.
Oxidative stress values were alsomeasured in 30 healthy control
subjects (46e81 years old) who were matched with the 43 IPF
patients in gender and smoking history. The 43 IPF patients
comprised of 33 males and 10 females with an average age of
69.4 ± 8.9 years. Meanwhile, the healthy control subjects were
composed of 23 males and 7 females with an average age of
65.0 ± 11.5 years. In both groups, no smoker was included at the
time of the examination (Table 1).
Of the 43 IPF patients, 27 untreated patients who did not develop
any complications such as malignant tumors and infectious disease
and had been followed-up for six months were subjected to retro-
spective analyses on changes in serum oxidative stress values and
respiratory function. 27 patients (24 men and 3 women) were aged
67.7 ± 8.4 years, and 23 were ex-smokers while 4 were nonsmokers.
Oxidative stress values were additionally measured in a total of
13 cases (9 men and 4 women) with acute exacerbation of IPF (AE-
IPF) before treatments (other than oxygen administration) were
initiated. 13 cases were consisted of 5 cases (among our 43 IPFcases) that occurred during follow-up at our hospital, and 8 addi-
tional cases who were diagnosed with IPF at another hospital and
transferred to our hospital at the time of AE-IPF. They were aged
67.4 ± 8.3 years, and 9 were ex-smokers while 4 were nonsmokers.
AE-IPF was diagnosed according to the following criteria [3]: IPF
was diagnosed previously or at the same time; unpredicted acute
worsening of dyspnea within 30 days; development of new
ground-glass opacity or consolidation with the background ﬁnd-
ings of reticular shadows or honeycomb lungs with the UIP pattern;
and exclusion of pulmonary infection, left heart failure, pulmonary
embolism, and acute lung injury with an already identiﬁed cause.
This study was approved by the ethical committee of our
institute, and written informed consent was obtained from the
patients and control subjects after detailed explanation.
2.2. d-ROMs test
Oxidative stress was evaluated by measurement of serum hy-
droperoxide by the d-ROMs test. Free Radical Analytical System 4
(FRAS 4, Wismerll Co. Ltd., Tokyo, Japan) was used for the test. The
principle of the test is based on the concept that the serum organic
hydroperoxide content reﬂects the free radical content that pro-
duces it. Standard test procedures are as follows. Blood samples
collected from peripheral vein of the patients were centrifuged at
4 C at 1500 g for 15 min, and 20 ml of serumwas mixed with acid
buffer solution (pH 4.8, R1 reagent of the kit) in a cuvette, which
was then supplemented with 20 ml of the chromogen (R2 reagent of
the kit). Serum hydroperoxide, reacting with the transition metal
ion released from the protein in the blood under acidic environ-
ments, changed to alkoxy or peroxy radicals. These newly produced
radicals oxidized the chromogen and yielded a purple product.
The concentration of the stable product was easily measured
with a spectrophotometer (absorbance at 505 nm). The normal
range of the test results was 250e300 U.CARR (Carratelli Units),
where 1 U.CARR corresponded to 0.8 mg/l of hydrogen peroxide.
Results exceeding 300 U.CARR indicated increased oxidative stress.
2.3. Serum markers and pulmonary function tests
Examination of serum markers and pulmonary function tests
were performed at the same time as the d-ROMs test. Biochemical
tests were done with JOEL BM-6050 (JOEL Ltd., Tokyo, Japan), while
serum KL-6 and SP-D were measured with an electrochemical
luminescence immunoassay kit (EIDIA, Tokyo, Japan; normal
range<500 U/ml) and an enzyme immunoassay kit (Yamasa Cor-
poration, Chiba, Japan; normal range<110 U/ml), respectively. For
assessing respiratory function, the CHESTAC-9800 pulmonary
function test (Chest, Tokyo, Japan) was employed. FVC was
measured at least three times, and the highest value was recorded.
DLCOwasmeasured by the helium diffusionmethodwith one-time
breath holding.
2.4. Statistical analysis
In cases with no annotation, statistics were expressed as
average ± tandard deviation. For comparison of oxidative stress
Table 2
Oxidative stress, pulmonary function, and serum marker levels of patients with IPF.
Normal value IPF (n ¼ 43)
d-ROMs (U.CARR) mean ± SD
median, interquartile range
383 ± 76
366, 339e443
FVC (ml) 2390 ± 890
FVC (% predicted) 76.9 ± 22.3
%Dlco (% predicted) 64.7 ± 22.4
PaO2 (mmHg) 71.9 ± 13.4
LDH (IU/L) 120e240 221 ± 40.4
KL6 (U/ml) <500 1259 ± 1030
SP-D (ng/ml) <110 292 ± 197
d-ROMs, Diacron Reactive Oxygen Metabolites; FVC, forced vital capacity; DLCO,
diffusing capacity; KL6, sialylated carbohydrate antigen; SP-D, surfactant protein D.
Table 3
Correlation of oxidative stress with age, pulmonary function tests, PaO2, and serum
markers in 43 patients with IPF.
Oxidative stress
p rs
Age 0.95 0.01
FVC (% predicted) 0.06 0.295
Dlco (% predicted) 0.582 0.1
PaO2 (mmHg) 0.12 0.19
LDH (IU/L) 0.08 0.28
KL-6 (U/ml) 0.51 0.11
SP-D (ng/ml) 0.85 0.001
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employed, while Wilcoxon's rank sum test was used for the com-
parison between the baseline and follow-up values. For analysis of a
correlation between different parameters, Spearman's rank corre-
lation coefﬁcient was used. A p-value less than 0.05 was considered
statistically signiﬁcant. Statistical analysis software SPSS 12.0 was
employed.
3. Results
3.1. IPF patients and controls
The pulmonary function tests and evaluation of serum bio-
markers performed in the 43 IPF patients revealed that FVC was
2390 ± 890 (ml) and 76.9 ± 22.3 (% predicted), DLCO (% predicted)
was 64.7 ± 22.4 (%), serum marker LDH was 221 ± 40.4 (IU/l), KL-6
was 1259 ± 1030 (U/ml), and SP-D was 292 ± 197 (ng/ml) (Table 2).
Oxidative stress values in the 43 IPF patients were 383 ± 76
(U.CARR) (Table 2), and were signiﬁcantly higher than in controls
[median, interquartile range (IQR): 366, 339e443 vs. 289, 257e329
U.CARR, respectively; p < 0.01] (Fig.1). Oxidative stress values
showed no signiﬁcant correlation with DLCO (% predicted)
(p ¼ 0.58, rs ¼ 0.1) or FVC (% predicted) (p ¼ 0.06, rs ¼ 0.295). In
addition, oxidative stress values had no signiﬁcant correlation with
LDH, KL6, or SP-D (Table 3).Fig. 1. Oxidative stress levels in patients with IPF and controls. The two groups differ
signiﬁcantly as indicated.3.2. Changes over time
Changes in the different parameters were evaluated at the six
month follow-up in 27 untreated patients. FVC (ml) and DLCO (%
predicted) were signiﬁcantly decreased compared with the base-
lines, by 131 ± 174 ml and 9.1 ± 9.4%, respectively, after 6 months.
Therewas no signiﬁcant change in LDH, KL-6, or SP-D during the
follow-up period. Oxidative stress values were signiﬁcantly
increased in 22 of 27 patients as compared to baseline values
(median, IQR: 353, 311e398 at baseline to 385, 345e417 at follow-
up U.CARR, p < 0.01) (Table 4).
The median (IQR) elevation in the oxidative stress value after 6
months was 24.0 (6.0e49.0) U.CARR/year, which was negatively
correlated with FVC changes after 6 months (rs ¼ 0.60, p < 0.01)
and baseline DLCO (rs ¼ 0.44, p < 0.05) (Figs. 2 and 3).
As the decrease in FVC vary from rapid to slow, the cases were
classiﬁed into “rapid progressor” as the cases which showed a 5% or
more decrease in FVC (ml) after 6 months, and “slow progressor” as
the cases which showed a less than 5% decrease in FVC (ml). There
was no signiﬁcant difference in the baseline oxidative stress value
between rapid progressor (n ¼ 13), and slow progressor (n ¼ 14),
but the oxidative stress value increased signiﬁcantly more in “rapid
progressor” after 6 months (median, IQR: 31.3, 21.6e52.6 vs. 14.3,
7.1e25.0 U.CARR, respectively, p < 0.01) (Fig. 4).3.3. Acute exacerbation of IPF
In the 13 patients with acute exacerbation of IPF, the PaO2 to
FiO2 (P/F) ratiowas 177.8 ± 54.3, while LDHwas 382± 125 IU/l, KL-6
was 1815 ± 1030 IU/l, and SP-D was 505 ± 467 ng/ml (Table 5).
The oxidative stress values in these patients with acute exac-
erbation were signiﬁcantly higher as compared to that in patients
with stabilized IPF (median, IQR: 587, 523e667 vs. 366, 339e443
U.CARR, p < 0.01) (Fig. 5). In all ﬁve AE-IPF cases who were part ofTable 4
Change in pulmonary function, serum marker levels, and oxidative stress in 27
patients with IPF.
Baseline After 6 months p-value
N 27
Sex (m/f) 24/3
Smoker/ex-smoker/non-smoker 0/23/4
Age 67.7 ± 8.4
FVC (ml) 2680 ± 900 2550 ± 904 P < 0.01
FVC(% predicted) 82.6 ± 23.6 78.9 ± 24.4 P < 0.01
Dlco (% predicted) 68.3 ± 19.3 59.8 ± 17.3 P < 0.05
LDH (IU/L) 217 ± 37 216 ± 37 N.S
KL6 (U/ml) 1150 ± 886 1065 ± 889 N.S
SP-D (ng/ml) 315 ± 208 269 ± 160 N.S
d-ROMs (U.CARR) mean ± SD
median, interquartile range
359 ± 66
353,311e398
385 ± 65
385,345e417
P < 0.01
Fig. 2. Change in oxidative stress correlates negatively with change in FVC.
Fig. 4. Change in oxidative stress was signiﬁcantly higher in “rapid progressor” than in
“slow progressor”. rapid progressor: 5% or more decrease in FVC after 6 months; slow
progressor: less than 5% decrease in FVC after 6 months.
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erbation (data not shown).
Among these 13 patients, the oxidative stress value range was
401e724 in 9 patients who were inhaled oxygen during measure-
ment, while 543e711 in 4 patients without oxygen administration
during measurement.
4. Discussion
The oxidative stress level in IPF patients was signiﬁcantly higher
as compared to normal controls in the present study, consistent
with the report by Daniil et al. [11]. Increased oxidative stress in the
lungs in situ leads to inﬂux of hydroperoxide into the blood, which
is measured by the d-ROMs test and is a more stable substanceFig. 3. Change in oxidative stress correlates negatively with baseline DLCO.compared with reactive oxygen intermediate (ROI), and is expected
to increase d-ROMs values.
In contrast to the previous ﬁndings by Daniil et al., our data
showed that the baseline oxidative stress value had no signiﬁcant
correlation with DLCO or FVC.
The serum oxidative stress value reﬂects systemic oxidative
stress, and it is understandable that it is not always correlated with
the baseline severity of IPF. On the other hand, serum oxidative
stress values signiﬁcantly increased after six months in the follow-
up study of 27 cases. During this period, there was no disease
development or treatment intervention, and the increase of serum
stress value was considered a reﬂection of a time-course elevation
in oxidative stress in the lungs.
It has been suggested that time-course change in respiratory
function rather than the baseline value is more important in the
evaluation of IPF. Collard et al. reported that the degree of pulmo-
nary dysfunction at baseline had no correlation with the speed of
aggravation of pulmonary function in IPF, and change in pulmonary
function over a period of 6e12 months rather than baseline values
was more reﬂective of prognosis of IPF [15]. Jegal et al. followed-up
179 cases with ﬁbrotic interstitial pneumonia, and found that FVC
change, baseline DLCO, and gender were three independent prog-
nostic factors based on multivariate analyses [16]. In particular, FVC
change was underscored as a sensitive marker [17] and has been
employed as a major evaluation variable in recent clinical trials
[18e20].
Baseline FVC (% predicted) is inﬂuenced by not only the severity
of IPF, but also muscle strength and body build. Meanwhile, change
in FVC is unlikely to be inﬂuenced by factors other than IPF per se. It
is reasonable that change in FVC rather than baseline FVC is a
prognostic factor. In this study, the change in oxidative stress after
six months correlated with a decrease in FVC, which was consid-
ered the most important prognostic factor for IPF.
Unlike FVC, DLCO correlated with the baseline value. Jegal et al.
reported that baseline DLCO value and not FVC was a prognostic
factor. These results are attributable to the fact that DLCO decreases
before FVC decreases and DLCO, unlike FVC, is not associated with
Table 5
Characteristics of patients with acute exacerbation of IPF (AE-IPF). P/F ratio;
PaO2 to FiO2 ratio.
AE-IPF (n ¼ 13)
Sex, m/f 9/4
Age (yr) 67.4 ± 8.3
Smoker/ex-smoker/nonsmoker 0/9/4
P/F ratio 177.8 ± 54.3
LDH (IU/L) 382 ± 125
KL-6 (U/ml) 1815 ± 1030
SP-D (ng/ml) 505 ± 467
d-ROMs (U.CARR) mean ± SD
median interquartile range
583 ± 98
587, 523e667
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change in DLCO had no correlation with the change in oxidative
stress. As Jegal et al. suggested, DLCO measurements tend to ﬂuc-
tuate, which may explain these results [16].
Although a number of studies have investigated whether the
prognosis of IPF can be predicted by serum biomarkers, it remains
inconclusive. Yokoyama et al. reported that an increase in KL-6
levels was a poor prognostic factor for IPF, while Takahashi et al.
reported that increased SP-D was a poor prognostic factor for IPF
[21,22]. Meanwhile, Song et al. reported that neither KL-6 nor SP-D
alone was a poor prognostic factor for IPF [23]. The results of our
present study showed that pulmonary function at baseline had no
signiﬁcant correlation with KL-6 or SP-D, and there was no signif-
icant correlation between the change over time in these markers
and pulmonary function change. Taken together, no established
serummarker has been deﬁnitely established as a prognostic factor
for IPF, but our results show that change in the oxidative stress
value could be a reliable serum marker to predict the prognosis of
IPF.
As lung ﬁbrosis advances, vital capacity decreases in IPF, which
correlates with an increase in oxidative stress. Does increased
oxidative stress advance ﬁbrosis in IPF or does advancement of
ﬁbrosis increase oxidative stress? With regard to the relationship
between ﬁbrosis and oxidative stress in IPF, reactive oxygen species
(ROS) accelerate the production of transforming growth factorFig. 5. Oxidative stress levels in patients with acute exacerbation of IPF (AE-IPF) and in
stable IPF patients. The two groups differ signiﬁcantly as indicated.(TGF)-b, a cytokine involved in ﬁbrosis, in epithelial cells [12,13],
while TGF-b promotes ROS production in ﬁbroblasts [14]. These
results suggest that a positive feedback may exist between pul-
monary ﬁbrosis and oxidative stress. Increased oxidative stress
accelerates pulmonary ﬁbrosis following alveolar cell injury, and
progression of pulmonary ﬁbrosis may potentially increase oxida-
tive stress over time.
Baseline oxidative stress values showed no correlation with the
severity of IPF. Oxidative stress is increased even in mild IPF cases
with normal respiratory function. Is oxidative stress increased prior
to the onset of IPF?
Recently, it has been elucidated that excessive iron load in the
lower airway is involved in oxidative stress in IPF [24]. In addition,
it was demonstrated that an HFE genetic polymorphism was
involved in the mechanism [25]. Increased oxidative stress in IPF
may potentially be determined by the background genetic poly-
morphism proﬁle before the onset of IPF.
No report has investigated the relationship between AE-IPF and
oxidative stress, which remains to be elucidated. In this study,
oxidative stress values were signiﬁcantly higher in the 13 AE-IPF
cases than in the stable IPF cases, and were increased before the
occurrence of AE in all ﬁve cases in which oxidative stress values
were measured before AE. Although oxygen administration during
AE may inﬂuence oxidative stress values, these values ranged from
543 to 711 in 4 cases without oxygen administration during mea-
surement and 401 to 724 in 9 cases with oxygen administration
during measurement, which suggested that there is little associa-
tion between the increase in oxidative stress values and oxygen
administration. In our present study, oxidative stress values were
increased not only in the chronic stage of IPF, but also during AE.
Nevertheless, how oxidative stress is increased in AE-IPF remains
unclear.
There are limitations to this study; the study was retrospective
and selection bias could not be excluded, and oxidative stress in the
lungs was measured in serum which may not be the most appro-
priate specimen. For evaluation of oxidative stress in the lungs in
situ, d-ROMs test using BALF samples may be more appropriate.
Rahman et al. measured oxidative stress values in both serum and
BALF, and found that both were higher in IPF patients than in
controls [9]. However, measurement with BALF is too invasive to
examine change over a period of time. Another sample type to
examine oxidative stress in the lungs of IPF patients is exhaled
breath condensatewhich can be evaluated to obtain information on
the lungs in situ and for a variety of respiratory diseases on a trial
basis [26]. It was also reported that oxidative stress measurement
with exhaled breath condensate was unaffected by systemic dis-
eases [27]. However, like the report by Daniil et al. [11], the above
studies performed single measurement in each patient. Serial
investigation of oxidative stress markers in expired breath
condensate may be more important.
Since an imbalance between oxidative stress and anti-oxidative
potency is involved in ﬁbrosis in IPF, “anti-oxidative therapy” to
suppress oxidative stress may potentially be useful for treatment of
IPF. In bleomycin-induced lung injury, an animal model of pulmo-
nary ﬁbrosis, PC-SOD (lecithinized superoxide dismutase) sup-
pressed the disease by eliminating cytotoxicity of superoxide [28].
In addition, we reported that administration of PC-SOD was effec-
tive for treating steroid-resistant interstitial pneumonia [29]. N-
acetylcysteine has been reported to be effective for IPF, and the
mechanism of action is probably related to its anti-oxidant effect
[18]. Pirfenidone, which has been conﬁrmed to suppress the pro-
gression of IPF, is thought to have anti-oxidative activity as well as
anti-ﬁbrotic activity [30].
In addition to anti-inﬂammatory and anti-ﬁbrotic therapies,
anti-oxidant treatment may also be used for IPF, and lecithinized
Y. Matsuzawa et al. / Pulmonary Pharmacology & Therapeutics 32 (2015) 1e66superoxide dismutase is a strong candidate. Measuring oxidative
stress markers before and after anti-oxidant therapy for IPF is ex-
pected to be useful.
5. Conclusions
As IPF progressed, oxidative stress was signiﬁcantly increased
which was signiﬁcantly correlated with a reduction in FVC. In AE-
IPF cases, oxidative stress was remarkably increased. These re-
sults suggested that oxidative stress may not only be the cause of
IPF, but may also play an important role in its deterioration.
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